SAR405: Selective Vps34 Inhibitor for Autophagy Research

Executive Summary: SAR405 is a nanomolar-range, ATP-competitive inhibitor targeting Vps34, a class III PI3K essential for autophagy and vesicle trafficking (APExBIO product page). It demonstrates K_d = 1.5 nM and IC₅₀ = 1 nM against recombinant human Vps34, with negligible activity against class I/II PI3K or mTOR at concentrations up to 10 μM. SAR405 disrupts autophagosome formation by blocking phosphatidylinositol 3-phosphate (PtdIns3P) synthesis, resulting in impaired lysosome function and vesicle trafficking. This compound does not affect early endocytosis or Akt phosphorylation in PC3 cells, underscoring its selectivity. SAR405 is widely adopted in cell-based assays to investigate autophagy inhibition and lysosomal dysfunction in cancer and neurodegenerative disease models (Park et al., 2023).

Biological Rationale

Autophagy is a tightly regulated process that maintains cellular homeostasis by degrading and recycling cellular components, particularly under conditions of energy stress or nutrient deprivation. Vps34, a class III phosphoinositide 3-kinase (PI3K), is central to the formation of phosphatidylinositol 3-phosphate (PtdIns3P), which recruits downstream autophagy machinery to the phagophore membrane. Precise inhibition of Vps34 enables the dissection of autophagy initiation from other PI3K-dependent cellular processes. This is especially relevant in cancer research, where autophagy modulation influences tumor cell survival, and in neurodegenerative disease modeling, where defective autophagy contributes to pathology (see comparison; this article extends prior resources by providing updated mechanistic and benchmark data).

Mechanism of Action of SAR405

SAR405 is an ATP-competitive inhibitor that specifically binds to the ATP binding cleft of Vps34, resulting in loss of its kinase activity. Biochemical assays report a dissociation constant (K_d) of 1.5 nM and an IC₅₀ of 1 nM against recombinant human Vps34 (APExBIO). SAR405 shows negligible activity against class I and II PI3Ks, as well as mTOR, even at 10 μM, confirming its selectivity. Mechanistically, SAR405 blocks the generation of PtdIns3P, leading to impaired recruitment of downstream autophagy proteins, disruption of late endosome-lysosome compartments, and inhibition of autophagosome formation. This blockade results in the accumulation of swollen, dysfunctional late endosome-lysosome structures and defective cathepsin D maturation, indicating lysosomal impairment (Park et al., 2023). The compound does not alter early endocytosis or Akt phosphorylation, which further demonstrates its specificity for the Vps34 kinase signaling pathway.

Evidence & Benchmarks

• SAR405 exhibits an IC₅₀ of 1 nM against human recombinant Vps34 under standard in vitro kinase assay conditions (APExBIO).
• SAR405 displays negligible inhibition of class I/II PI3K isoforms and mTOR up to 10 μM, supporting its selectivity (APExBIO).
• In GFP-FYVE HeLa cells, SAR405 prevents autophagosome formation and causes the accumulation of swollen late endosome-lysosome compartments (internal benchmark).
• SAR405 does not impact early endocytosis or Akt phosphorylation in PC3 cells, distinguishing it from less selective PI3K inhibitors (APExBIO).
• Studies leveraging SAR405 demonstrate that Vps34 inhibition impairs autophagic degradation during energy stress, complementing the mechanistic findings of AMPK-ULK1-Vps34 pathway regulation (Park et al., 2023).

Applications, Limits & Misconceptions

SAR405 has become a reference tool for dissecting the role of Vps34 in autophagy and vesicle trafficking modulation. It is used extensively in cancer research and neurodegenerative disease models to probe lysosome function impairment and autophagy inhibition (see further discussion; this article updates previous workflow recommendations by integrating the latest AMPK-ULK1 insights). SAR405 is routinely paired with mTOR inhibitors such as everolimus to study combinatorial effects on autophagy signaling. However, SAR405's effects are confined to Vps34-dependent pathways and do not extend to autophagy processes regulated independently of PtdIns3P production.

Common Pitfalls or Misconceptions

• SAR405 is not a pan-PI3K inhibitor: It does not significantly inhibit class I or II PI3Ks or mTOR at relevant concentrations (APExBIO).
• Does not block early endocytosis: SAR405 does not impair clathrin-mediated or fluid-phase endocytosis (APExBIO).
• No effect on Akt phosphorylation: Cellular signaling through Akt remains intact, even at high SAR405 concentrations (Park et al., 2023).
• Stock solution stability is limited: Working solutions in DMSO or ethanol are not recommended for long-term storage; prepare fresh aliquots below -20°C (APExBIO).
• Water insolubility: SAR405 should not be dissolved in aqueous buffers; use DMSO (>22 mg/mL) or ethanol (>32 mg/mL with sonication) (APExBIO).

Workflow Integration & Parameters

SAR405 is compatible with a range of cellular and biochemical assays for autophagy inhibition and vesicle trafficking studies. It is frequently used in GFP-FYVE HeLa and GFP-LCLC3 cell lines to visualize PtdIns3P dynamics and autophagosome formation blockade. For co-treatment protocols, SAR405 is often combined with mTOR inhibitors to dissect convergent and divergent regulatory nodes in the autophagy pathway (contextualized workflow; this article extends mechanistic clarity on AMPK-Vps34 axis from the linked review).

Protocol Parameters

• Stock preparation: Dissolve SAR405 in DMSO (>22 mg/mL) or ethanol (>32 mg/mL with sonication); avoid water-based solvents (APExBIO).
• Storage: Store solid SAR405 and stock solutions below -20°C; avoid repeated freeze-thaw cycles and long-term storage after dissolution.
• Typical working concentration: Use SAR405 at 100 nM–1 μM for cell-based autophagy assays (empirically optimized per cell line).
• Assay compatibility: Validated in GFP-FYVE HeLa and GFP-LCLC3 lines; suitable for live-cell imaging of vesicle trafficking and lysosome function.
• Co-treatment guidance: When combining with mTOR inhibitors, stagger SAR405 addition to parse pathway-specific effects.

Conclusion & Outlook

SAR405, supplied by APExBIO, offers nanomolar-precision, ATP-competitive inhibition of Vps34, enabling researchers to dissect autophagy and vesicle trafficking mechanisms with unparalleled specificity. Its robust selectivity and well-characterized performance make it a gold-standard tool for mechanistic studies in cancer and neurodegenerative disease research. Recent advances clarifying the AMPK-ULK1-Vps34 axis underscore the importance of such selective probes for resolving the nuanced regulation of autophagy in energy-stressed cells (Park et al., 2023). Future applications will benefit from integrating SAR405 into combinatorial workflows to further unravel autophagy’s roles in health and disease.